← Leaderboards
Henry B Koon
Beth Israel Deaconess Medical Center
$1,202,793
Attributed
$1,202,793
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $378.2K · FY2005–07$500K$375K$250K$125K$0
'05
'06
'07
Funding mix
By agency
NIH$1,202,793 · 4
By mechanism
K08$651,645 · 1
R21$511,875 · 1
M01$39,273 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Salvia Jain$1,304,580
- Christopher Carpenter$3,201,422
- John Louis Rinn$12,414,206
- John Clohessy$408,289
Others in their field
Top investigators on “Site Directed Mutagenesis”
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Richard J Ulevitch · Scripps Research Institute$27,055,189
- Myron Fredric Goodman · University Of Southern California$18,982,784
- Pieter J. De Jong · Children'S Hospital &Res Ctr At Oakland$18,178,966
- Richard C. Mohs · Mount Sinai School Of Medicine Of Nyu$17,686,819
- Keith W Miller · Massachusetts General Hospital$16,440,674
Research focus
Site Directed MutagenesisEnzyme Induction /RepressionNonhodgkin'S LymphomaTransfection /Expression VectorCell LinePhosphatidylinositol 3 KinaseProtein Tyrosine KinaseWestern BlottingsLuciferin MonooxygenaseLaboratory MousePlatelet Derived Growth FactorCd AntigensPhospholipase CBiological Signal TransductionPhosphorylationProtein Protein InteractionNeoplastic TransformationKaposi'S SarcomaImmunoprecipitationOncoprotein P21Clinical Trial Phase IiGel Mobility Shift AssayEnzyme ActivityGene Targeting
Grant awards (11)
NPM-ALK & CD30 Signaling in Anaplastic Cell Lymphoma$65,164
K08 · FY2007 · CA · contact PI
GLEEVEC IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$8,561
M01 · FY2007 · RR · contact PI
NPM-ALK & CD30 Signaling in Anaplastic Cell Lymphoma$130,329
K08 · FY2006 · CA · contact PI
GLEEVEC IN PATIENTS WITH HIV RELATED KAPOSI'S SARCOMA$30,712
M01 · FY2006 · RR · contact PI
Phase II Trial on Imatinib in Kaposi's Sacroma$217,405
R21 · FY2005 · CA
NPM-ALK &CD30 Signaling in Anaplastic Cell Lymphoma$130,329
K08 · FY2005 · CA
Phase II Trial on Imatinib in Kaposi's Sacroma$30,442
R21 · FY2005 · CA
Phase II Trial on Imatinib in Kaposi's Sacroma$264,028
R21 · FY2004 · CA
NPM-ALK &CD30 Signaling in Anaplastic Cell Lymphoma$130,329
K08 · FY2004 · CA
NPM-ALK &CD30 Signaling in Anaplastic Cell Lymphoma$130,329
K08 · FY2003 · CA
NPM-ALK &CD30 Signaling in Anaplastic Cell Lymphoma$65,165
K08 · FY2002 · CA